Maternal Stress During Pregnancy and Offspring Depression.

A. Sourander

DOI: https://doi.org/10.1016/j.jaac.2016.06.003

2016-08-01

Abstract:

What problem does this paper attempt to address?

Efficacy and safety of ciprofol (HSK3486) for procedural sedation and anesthesia induction in surgical patients: A systematic review and meta-analysis

Jiaxuan Wen,Chen Liu,Xueying Ding,Zimeng Tian,Wenyu Jiang,Xiuhong Wei,Xin Liu

DOI: https://doi.org/10.1016/j.heliyon.2023.e22634

IF: 3.776

2023-11-26

Heliyon

Abstract:Background: Ciprofol (HSK3486) is a novel gamma-aminobutyric acid type A (GABAA) receptor agonist that has attracted wide attention because of its lower injection pain and fewer adverse events. We summarized all available evidence and analyzed the efficacy and safety of ciprofol during procedural sedation and anesthesia induction. Methods: An electronic search of PubMed, Embase, Cochrane Library, Web of Science, Google Scholar, Science Direct, the Chinese National Knowledge Infrastructure, Wan Fang Data, and the VIP Chinese Journal Service platform was conducted from inception of databases to March 1, 2023. Risk ratio (RR) and mean difference (MD) with 95 % confidence interval (CI) were used separately for binary categorical and continuous variables. We performed trial sequential analysis and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to judge the certainty of evidence. Results: Fifteen randomized controlled trials with 2441 patients were included in this study. Ciprofol showed similar advantages to propofol in terms of induction success rate (RR = 1, 95 % CI = 0.99, 1.01, moderate certainty) and induction time (MD = 3.31, 95 % CI = -0.34, 6.95, low certainty), but did not increase the incidence of adverse events (RR = 0.88, 95 % CI = 0.78, 1.00, very low certainty), such as bradycardia (RR = 0.96, 95 % CI = 0.77, 1.21, high certainty), hypoxia (RR = 0.79, 95 % CI = 0.46, 1.37, p = 0.40, moderate certainty) and other adverse events. Although it may be associated with a longer time to be fully alert (MD = 1.22, 95 % CI = 0.32, 2.12, very low certainty), ciprofol significantly reduced injection pain (RR = 0.15, 95 % CI 0.09, 0.24, low certainty) and may have reduced the incidence of hypotension (RR = 0.77, 95 % CI = 0.63, 0.94, low certainty) and respiratory depression (RR = 0.29, 95 % CI = 0.15, 0.56, moderate certainty). Conclusion: Ciprofol and propofol had similar effects on most outcomes. While the time to full alertness may be prolonged, injection pain was significantly reduced, and hypotension and respiratory depression may be reduced compared with propofol. We believe that ciprofol is an effective alternative to intravenous anesthetic agents.
Identification of testis specific calcineurin beta subunit isoform by a monoclonal antibody and detection of a specific six amino acid sequence.

H. Nishio,H. Matsui,S. Etoh,L. J. Moia,M. Tokuda,T. Itano,O. Hatase

DOI: https://doi.org/10.1016/S0006-291X(05)80108-1

1992-01-15

Abstract:
The sensitivity index, a calculation to improve the choice of antibacterial therapy.

D. Elad

DOI: https://doi.org/10.1093/JAC/27.2.250

1991-02-01

Journal of Antimicrobial Chemotherapy

Abstract:
Efficacy and safety of Ciprofol compared with Propofol during general anesthesia induction: A systematic review and meta-analysis of randomized controlled trials (RCT)

Syed Muhammad Muneeb Akhtar,Areeba Fareed,Mirha Ali,Muhammad Sohaib Khan,Abraish Ali,Munazza Mumtaz,Robert Kirchoff,Muhammad Sohaib Asghar

DOI: https://doi.org/10.1016/j.jclinane.2024.111425

IF: 9.375

2024-02-29

Journal of Clinical Anesthesia

Abstract:Background Ciprofol, a newer entrant with similarities to propofol, has shown promise with a potentially improved safety profile, making it an attractive alternative for induction of general anesthesia. This meta-analysis aimed to assess the safety and efficacy of ciprofol compared with propofol during general anesthesia induction. Methods A comprehensive literature search was conducted using PubMed, Clinical Trial.gov , and Cochrane Library databases from inception to July 2023 to identify relevant studies. All statistical analyses were conducted using R statistical software version 4.1.2. Results Thirteen Randomized Controlled Trials (RCTs) encompassing a total of 1998 participants, were included in our analysis. The pooled analysis indicated that Ciprofol was associated with a notably lower incidence of pain upon injection [RR: 0.15; 95% CI: 0.10 to 0.23; I^2 = 43%, p < 0.0000001] and was non-inferior to propofol in terms of anesthesia success rate [RR: 1.00; 95% CI: 0.99 to 1.01; I^2 = 0%; p = 0.43]. In terms of safety, the incidence of hypotension was significantly lower in the ciprofol group [RR:0.82; 95% CI:0.68 to 0.98; I^2 = 48%; p = 0.03]. However, no statistically significant differences were found for postoperative hypertension, bradycardia, or tachycardia. Conclusion In conclusion, Ciprofol is not inferior to Propofol in terms of its effectiveness in general anesthesia. Ciprofol emerges as a valuable alternative sedative with fewer side effects, especially reduced injection pain, when compared to Propofol. Summary Propofol, frequently utilized as an anesthetic, provides swift onset and quick recovery. However, it has drawbacks such as a narrow effective dosage range and a high occurrence of adverse effects, particularly pain upon injection. Ciprofol, a more recent drug with propofol-like properties, has demonstrated promise and may have an improved safety profile, making it a compelling alternative for inducing general anesthesia. This meta-analysis compared the safety and effectiveness of Ciprofol with Propofol for general anesthesia induction in a range of medical procedures, encompassing thirteen Randomized Controlled Trials (RCTs) and 1998 individuals. The pooled analysis indicated that Ciprofol was associated with a notably lower incidence of pain upon injection [RR: 0.15; 95% CI: 0.10 to 0.23; I^2 = 43%, p < 0.0000001] and was non-inferior to propofol in terms of anesthesia success rate [RR: 1.00; 95% CI: 0.99 to 1.01; I^2 = 0%; p = 0.43]. In terms of safety, the incidence of hypotension was significantly lower in the ciprofol group [RR:0.82; 95% CI:0.68 to 0.98; I^2 = 48%; p = 0.03]. However, no statistically significant differences were found for hypertension, bradycardia, or tachycardia. In conclusion, ciprofol is equally effective at inducing and maintaining general anesthesia as propofol. When compared to propofol, ciprofol is a better alternative sedative for operations including fiberoptic bronchoscopy, gynecological procedures, gastrointestinal endoscopic procedures, and elective surgeries because it has less adverse effects, most notably less painful injections.

anesthesiology
Twenty-first century international lawmaking for alcohol control.

Allyn L. Taylor,Ibadat Dhillon

DOI: https://doi.org/10.1111/add.12063

2013-03-01

Addiction

Abstract:
Efficacy and safety of ciprofol versus propofol for induction of general anaesthesia or sedation: A systematic review and meta-analysis of randomised controlled trials

Abdallah Saeed,Mariam Elewidi,Ahmad Nawlo,Amr Elzahaby,Asmaa Khaled,Abdalla Othman,Mohamed Abuelazm,Basel Abdelazeem

DOI: https://doi.org/10.4103/ija.ija_104_24

Abstract:Background and aims: Propofol has been used in medical practice as an anaesthetic drug for producing and sustaining general anaesthesia due to its advantages. However, it also has drawbacks, including injection-related discomfort. Recently, ciprofol has emerged as a promising anaesthetic drug that may overcome many drawbacks associated with propofol. In this systematic review and meta-analysis, we assess the efficacy and safety of ciprofol compared to propofol in different anaesthesia procedures. Methods: The study protocol was registered in the International Prospective Register of Systematic Reviews (ID: CRD42023458170). Central, PubMed, EMBASE, Scopus and WOS were searched for English literature until 26 February 2024. Meta-analysis was performed using RevMan. The risk of bias was assessed using the RoB 2.0 tool. Results were reported as risk ratios (RRs), mean differences (MDs) and 95% confidence intervals (CIs). Results: Nineteen randomised controlled trials were included in our analysis, with 2841 participants. There was no difference between ciprofol and propofol in the success rate of endoscopy (RR: 1.01, 95% CI: 0.99, 1.02; P = 0.44), while ciprofol showed a significant increase in the success rate of general anaesthesia/sedation (RR: 1.01, 95% CI: 1.00, 1.02; P = 0.04). Ciprofol showed significantly lower pain on injection (RR: 0.14, 95% CI: 0.09, 0.22; P < 0.001), lower adverse events (RR: 0.80, 95% CI: 0.69, 0.92; P = 0.002) and higher patient satisfaction (standardised mean difference (SMD): 0.36, 95% CI: 0.24, 0.48; P < 0.001). Conclusion: Ciprofol exhibited a comparable efficacy to propofol in inducing general anaesthesia and sedation with fewer adverse events, less pain on injection and higher patient satisfaction. These collective findings may suggest that ciprofol can be used as an alternative drug to ensure effective general anaesthesia/sedation induction in the future.
Efficacy and Safety of Ciprofol Versus Propofol for the Induction of Anesthesia in Adult Patients: a Multicenter Phase 2a Clinical Trial

Qianmei Zhu,Zhen Luo,Xia Wang,Dongxin Wang,Jun Li,Xinchuan Wei,Jun Tang,Shanglong Yao,Wen Ouyang,Wensheng Zhang,Yunxia Zuo,Xiao Wang,Jin Liu

DOI: https://doi.org/10.1007/s11096-022-01529-x

IF: 2.305

2023-01-01

International Journal of Clinical Pharmacy

Abstract:Background Ciprofol is a novel 2, 6-disubstituted phenolic derivative anesthetic that binds to the gamma-aminobutyric acid-A receptor. Aim To determine the equally potent dose of ciprofol compared with propofol as an induction agent for general anesthesia in patients undergoing selective surgery, and to assess its safety. Method A total of 109 patients undergoing selective non-emergency, non-cardiothoracic or non-neurosurgical surgery requiring tracheal intubation for general anesthesia were enrolled. Ten patients per group were assigned to ciprofol-0.3, 0.4 and 0.5 mg/kg, and propofol-2.0 or 2.5 mg/kg groups, respectively to receive an intravenous bolus dose. An additional 20 patients were enrolled in the ciprofol-0.3, 0.5 or propofol-2.0 mg/kg groups. The primary outcome was the success rate of induction defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) ≤ 1 after the initial bolus dose. The secondary outcomes included the time to reach MOAA/S ≤ 1, the time to loss of the eyelash reflex, the incidences and severity of adverse events (AEs). Results The success rates were 100% for all 5 groups. The mean time to MOAA/S ≤ 1 and the time to loss of the eyelash reflex were not different among the 5 groups, regardless of whether a top-up dose was needed. There were no significant differences in the incidences and severity of AEs in the dose ranges investigated of ciprofol vs. propofol. Conclusion The efficacy and safety of a single bolus dose of ciprofol-0.5 mg/kg for the general anesthesia induction in selective surgery patients was comparable to that of propofol-2.0 mg/kg. Trial registration Clinicaltrials.gov, NCT03698617, retrospectively registered.
Effects of Ciprofol for the Induction of General Anesthesia in Patients Scheduled for Elective Surgery Compared to Propofol: a Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study

X. Wang,J. Liu,Y-X Zuo,Q-M Zhu,X-C Wei,X-H Zou,A-L Luo,F-X Zhang,Y-L Li,H. Zheng,H. Li,S. Wang,D-X Wang,Q-L Guo,C-M Liu,Y-T Wang,Z-Q Zhu,G-Y Wang,Y-Q Ai,M-J Xu

DOI: https://doi.org/10.26355/eurrev_202203_28228

2022-01-01

Abstract:OBJECTIVE: Ciprofol is a newly developed intravenous sedative-hypnotic drug. The objective of the study was to prove whether ciprofol was non-inferior to propofol for the successful induction of general anesthesia. The ideal post-induction sedation level was assessed by comparing patients’ clinical symptoms and their hemodynamic effects in responding to noxious stimuli, mostly tracheal intubation and bispectral index (BIS) alterations following ciprofol/propofol administration. PATIENTS AND METHODS: In this multi-center, randomized, double-blind phase 3 trial, selective surgery patients were randomly assigned in a 1:1 ratio to either ciprofol 0.4 mg/kg (n = 88) or propofol 2.0 mg/kg (n = 88) groups. The primary endpoint was the percentage of patients with successful anesthesia inductions. Secondary endpoints included the times to successful induction of general anesthesia and loss of the eyelash reflex, changes in BIS, as well as safety indicators. RESULTS: The anesthesia induction success rates for both ciprofol 0.4 mg/kg and propofol 2 mg/kg groups were 100.0%, with a 95% CI lower success limit of -4.18% difference between the two groups, indicating that ciprofol was non-inferior to propofol. For secondary outcomes, the average time to successful anesthesia and loss of the eyelash reflex were 0.91 min and 0.80 min for ciprofol and 0.80 min and 0.71 min for propofol, respectively. The pattern of BIS changes with ciprofol was similar to propofol and stable during the anesthesia maintenance period. Safety was comparable with 88.6% TEAEs in the ciprofol group compared to 95.5% in the propofol group. The incidence of injection pain was significantly lower in the ciprofol group compared to the propofol group (6.8% vs. 20.5%, p < 0.05). In addition, the patients treated with ciprofol had a lesser increase in blood pressure and heart rate, and fewer cases with BIS > 60 within 15 min of intravenous administration, which indicated that ciprofol may provide a better ideal sedation level during the post-induction period under an equivalent dosing regimen to propofol. CONCLUSIONS: Ciprofol for patients undergoing selective surgery is a new option for the induction of general anesthesia.
Efficacy and safety of ciprofol for sedation in outpatient gynecological procedures: a phase III multicenter randomized trial

Jing Xu,Mengchang Yang,Yuan Zeng,Xiao-Hua Zou,Jing-Hua Ren,Zhongyuan Xia,Hai-Hui Xie,Yong-Hao Yu,Ming-Jun Xu,Wei Chen,Dong-Xin Wang

DOI: https://doi.org/10.3389/fmed.2024.1360508

IF: 3.9

2024-04-23

Frontiers in Medicine

Abstract:Objective Ciprofol (also known as cipepofol and HSK3486), is a compound similar to propofol in chemical structure and hypnotic effect. Herein we evaluated the efficacy and safety of ciprofol for sedation in outpatient gynecological procedures. Methods This phase III multicenter randomized trial with a non-inferiority design was conducted in nine tertiary hospitals. We enrolled 135 women aged 18–65 years who were scheduled for ambulatory gynecological procedures. Patients were randomly assigned to receive either ciprofol (0.4 mg/kg for induction and 0.2 mg/kg for maintenance) or propofol (2.0 mg/kg for induction and 1.0 mg/kg for maintenance) sedation in a 2:1 ratio. Patients and investigators for data collection and outcome assessment were blinded to study group assignments. The primary outcome was the success rate of sedation, defined as completion of procedure without remedial anesthetics. The non-inferiority margin was set at −8%. Secondary outcomes included time to successful induction, time to full awake, time to meet discharge criteria, and satisfaction with sedation assessed by patients and doctors. We also monitored occurrence of adverse events and injection pain. Results A total of 135 patients were enrolled; 134 patients (90 patients received ciprofol sedation and 44 patients propofol sedation) were included in final intention-to-treat analysis. The success rates were both 100% in the two groups (rate difference, 0.0%; 95% CI, −4.1 to 8.0%), i.e., ciprofol was non-inferior to propofol. When compared with propofol sedation, patients given ciprofol required more time to reach successful induction (median difference [MD], 2 s; 95% CI, 1 to 7; p < 0.001), and required more time to reach full awake (MD, 2.3 min; 95% CI, 1.4 to 3.1; p < 0.001) and discharge criteria (MD, 2.3 min; 95% CI, 1.5 to 3.2; p < 0.001). Fewer patients in the ciprofol group were dissatisfied with sedation (relative risk, 0.21; 95% CI, 0.06 to 0.77; p = 0.024). Patients given ciprofol sedation had lower incidences of treat-emergent adverse events (34.4% [31/90] vs. 79.5% [35/44]; p < 0.001) and injection pain (6.7% [6/90] vs. 61.4% [27/44]; p < 0.001). Conclusion Ciprofol for sedation in ambulatory gynecological procedures was non-inferior to propofol, with less adverse events and injection pain. Clinical trial registration ClinicalTrials.gov, identifier NCT04958746.

medicine, general & internal
Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial

Peng Liang,Meng Dai,Xiao Wang,Dongxin Wang,Mengchang Yang,Xuemei Lin,Xiaohua Zou,Ke Jiang,Yalan Li,Liangrong Wang,Wangning Shangguan,Jinghua Ren,Hefan He

DOI: https://doi.org/10.1097/EJA.0000000000001799

2023-01-01

European Journal of Anaesthesiology

Abstract:BACKGROUNDHSK3486 (ciprofol) is a 2,6-disubstituted phenol derivative that acts like propofol as an agonist at the gamma-aminobutyric acid-A (GABA(A)) receptor.OBJECTIVETo investigate the efficacy and safety of HSK3486 for general anaesthesia induction and maintenance.DESIGNA single-blinded, randomised, parallel-group, phase 3 trial.SETTINGInvolving 10 study centres, from November 24, 2020 to January 25, 2021.PATIENTSA total of 129 patients undergoing nonemergency, noncardiothoracic, and nonneurosurgical elective surgery.INTERVENTIONPatients were randomly assigned at a 2:1 ratio into HSK3486 or propofol groups, to receive HSK3486 (0.4 mg kg(-1)) or propofol (2.0 mg kg(-1)) for induction before a maintenance infusion at initial rates of 0.8 and 5.0 mg kg(-1) h(-1), and were adjusted to maintain a bispectral index (BIS) of 40-60 until the end of surgery.MAIN OUTCOME MEASURESNoninferiority between the drugs was evaluated as the lower limit of the 95% confidence interval (CI) for the between-group difference in the success rate of anesthetic maintenance (primary outcome) >-8%. Secondary outcomes included successful anaesthetic induction, full alertness and spontaneous breathing recovery, time until leaving the postanaesthesia care unit and changes in BIS. Safety profiles were also measured.RESULTSOf 129 enrolled patients, 128 completed the trial, with 86 in the HSK3486 group and 42 in the propofol group. The success rate for the maintenance of general anaesthesia was 100% for both groups, and noninferiority of HSK3486 was confirmed (95% CI -4.28% to 8.38%). No significant differences were found between the two groups of patients with regard to secondary outcomes (all P > 0.05). There appeared to be a comparable incidence of treatment for emergency adverse events (TEAEs) (80.2% vs. 81.0%, P = 1.000) and drug-related TEAEs (57.0% vs. 64.3%, P = 0.451) in the HSK3486 and propofol groups.CONCLUSIONHSK3486 had a noninferior efficacy profile compared to propofol, exhibiting excellent tolerance.
Single-Artery Human Ear Graft Procurement: A Simplified Approach

J. Duisit,Hadrien Amiel,D. Debluts,L. Maistriaux,A. Gerdom,A. Bol,P. Gianello,C. Behets,B. Lengelé

DOI: https://doi.org/10.1097/PRS.0000000000003591

2017-09-01

Abstract:Summary: In the field of experimental facial vascularized composite tissue allotransplantation, a human auricular subunit model, pedicled on both superficial temporal and posterior auricular arteries, was described. Clinical cases of extensive auricular replantation, however, suggested that a single artery could perfuse the entire flap. In this study, variants of this single-pedicle approach have been studied, aiming to develop a more versatile replantation technique, in which the question of venous drainage has also been addressed. For arterial perfusion study, the authors harvested 11 auricular grafts, either on a single superficial temporal artery pedicle (n = 3) or a double superficial temporal and posterior auricular artery pedicle (n = 8). The authors then proceeded to selective barium injections, in the superficial temporal, posterior auricular, or both superficial temporal and posterior auricular arteries. Arteriograms were acquired with a micro–computed tomographic scan and analyzed on three-dimensionally reconstructed images. Venous drainage was investigated in eight hemifaces, carefully dissected after latex injection. Observations showed a homogenous perfusion of the whole auricle in all arterial graft variants. Venous drainage was highly variable, with either a dominant superficial temporal vein (37.5 percent), dominant posterior auricular vein (12.5 percent), or co-dominant trunks (50 percent). The authors demonstrated that auricular subunit vascularized composite tissue allotransplantation can be performed on a single artery, relying on the dynamic intraauricular anastomoses between superficial temporal artery and posterior auricular branches. Potentially, this vascular versatility is prone to simplify the subunit harvest and allows various strategies for pedicle selection. Venous drainage, however, remains inconstant and thus the major issue when considering auricular transplantation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.
Inhibitory Effect of Light on Growth-Supporting Properties of Eosin Methylene Blue Agar

R. L. Girolami,J. Stamm

DOI: https://doi.org/10.1128/aem.31.1.141-142.1976

1976-01-01

Applied and Environmental Microbiology

Abstract:Exposure of eosin methylene blue agar to visible light can alter the ability of that medium to support microbial growth. Proteus species were most sensitive to the photodynamic action.
Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial

Tong J Gan,Todd Bertoch,Ashraf S Habib,Pangke Yan,Rong Zhou,Yu-Ling Lai,Xiao Liu,Michael Essandoh,William L Daley,Adrian W Gelb

DOI: https://doi.org/10.1097/ALN.0000000000004886

IF: 8.986

2024-04-01

Anesthesiology

Abstract:Background: Propofol is an intravenous anesthetic associated with hypotension, respiratory depression, and injection-site pain. HSK3486 injectable emulsion (ciprofol) is a 2,6-disubstituted phenol derivative with fast onset and quick, stable recovery. Previous studies support HSK3486 as an effective, safe anesthetic with substantially less injection-site pain than propofol. The primary objective of this study was to investigate the noninferiority of HSK3486 compared with propofol in successful general anesthesia induction. Methods: Two hundred fifty-five participants were enrolled in HSK3486-304, a multicenter, randomized (2:1), double-blind, propofol-controlled, phase 3 study evaluating HSK3486 for general anesthesia induction in adults undergoing elective surgery with tracheal intubation. The primary endpoint was successful anesthesia induction, defined as 1 or less on the Modified Observer's Assessment of Alertness/Sedation scale. Key secondary endpoints were proportion of participants with injection-site pain on the Numerical Rating Scale of 1 or greater and a composite endpoint, including the proportion of participants successfully induced while maintaining the desired anesthetic depth and without substantial cardiac and respiratory events. Safety endpoints included adverse events, abnormal vital signs, and injection-site pain. Results: Two hundred fifty-one participants (HSK3486, n = 168; propofol, n = 83) were included in the analyses. General anesthesia was successfully induced in 97.0% versus 97.6% of participants with HSK3486 and propofol, respectively. The difference in success rate was -0.57% (95% CI, -5.4 to 4.2%); the noninferiority boundary of -8% was not crossed. Thirty participants (18.0%) had injection-site pain with HSK3486 versus 64 (77.1%) with propofol (P < 0.0001). Eighty-one participants (48.2%) with HSK3486 versus 42 (50.6%) with propofol (P = 0.8780) satisfied the composite endpoint. When injection-site pain was excluded, the incidence of treatment-emergent adverse events related to study drug was 17.9% for HSK3486 and 14.5% for propofol. Conclusions: The study met its primary objective and endpoint, demonstrating noninferiority of HSK3486 compared with propofol in successful anesthetic induction. Substantially less injection-site pain was associated with HSK3486 than with propofol.
The efficacy of ciprofol versus propofol on anesthesia in patients undergoing endoscopy: a systematic review and meta-analysis of randomized controlled trials

Jikai Liu,Aonan Hong,Jinfang Zeng,Xiao Liang

DOI: https://doi.org/10.1186/s12871-024-02721-4

IF: 2.376

2024-10-11

BMC Anesthesiology

Abstract:Ciprofol is a new intravenous anesthetic with a similar chemical structure to propofol. We aimed to compare the incidence of adverse actions like injection pain and time indexes of ciprofol versus propofol on anesthesia in patients undergoing endoscopy. We also compared anesthetists' satisfaction during the procedure.

anesthesiology
The characteristics of binding of human recombinant interferon-gamma to its receptor on human monocytes and human monocyte-like cell lines.

D. Finbloom,D. Hoover,L. Wahl

DOI: https://doi.org/10.4049/jimmunol.135.1.300

1985-07-01

Abstract:Interferon-gamma (IFN-gamma) induces many effector functions in macrophages, presumably through binding to cell surface receptors. Such receptors have been documented in murine macrophages. This report demonstrates that IFN-gamma interacts with a specific receptor on human monocytes and monocyte-like cell lines, U937 and HL60. Recombinant IFN-gamma (rIFN-gamma) was radioiodinated by using Bolton-Hunter reagent to high specific activity. 125I-rIFN-gamma bound in a specific and saturable manner. Saturation of binding sites occurred at 10(-9) M (300 U/ml); there were 4000 specific binding sites per cell for both monocytes and the cell lines. Purified lymphocyte-derived IFN-gamma as well as rIFN-gamma competed for binding sites with 125I-rIFN-gamma. There was no inhibition of binding of the 125I-rIFN-gamma by rIFN-alpha or rIFN-beta. The forward rate constant, k1, at 4 degrees C was about 8 X 10(5) M-1 sec-1 for each cell type studied. In the presence of excess ligand, the dissociation rate constant, k-1, was about 2 X 10(-4) sec-1. The Ka calculated from these constants (4 X 10(9) M-1) agreed closely with that calculated from experiments performed at equilibrium (8 X 10(9) M-1). Because the dissociation of rIFN-gamma from cells was enhanced in the presence of ligand, interactions between binding sites of a negative cooperative type could be operative. These studies demonstrate that rIFN-gamma binds in a specific and saturable manner and with high affinity to a receptor on human monocytes as well as monocyte-like cell lines.
Ciprofol: A Novel Alternative to Propofol in Clinical Intravenous Anesthesia?

Ming Lu,Jian Liu,Xikun Wu,Zhiqing Zhang

DOI: https://doi.org/10.1155/2023/7443226

2023-01-20

BioMed Research International

Abstract:Ciprofol is a novel compound that was independently developed in China. According to the Chinese product instructions approved by the China National Medical Products Administration and the information of official website, indications for ciprofol include sedation and anesthesia during the surgical/procedure of nontracheal intubation, induction and maintenance of general anesthesia, and sedation during intensive care. Ciprofol is a short-acting intravenous sedative based on the structural modification of propofol. Ciprofol has high efficacy, good selectivity, and fewer adverse reactions, indicating good clinical application potential. A series of clinical studies have been conducted to evaluate the sedative effect of ciprofol in various procedures and settings, including gastroscopy and colonoscopy, fiber-optic bronchoscopy, general anesthesia in elective surgeries, and mechanical ventilation in intensive care units. This review summarizes the chemical structure, pharmacodynamics, and pharmacokinetic properties of ciprofol. We also assessed the efficacy and safety of ciprofol by synthesizing the relevant clinical trial data.

biotechnology & applied microbiology,medicine, research & experimental
A role for computers in the management of dental education

D. Wastell,J. Lilley

DOI: https://doi.org/10.1111/j.1365-2923.1988.tb00409.x

1988-01-01

Medical Education

Abstract:Summary. The dental educator confronts increasing demands for technically demanding training against a background of factors working to reduce the clinical experience of students: less dental disease, new educational emphases and greater cost‐consciousness. A computer system is described which has run successfully for 7 years in the Department of Conservative Dentistry at Manchester University. This system enables better use to be made of declining teaching resources; it allows the department to make more accurate and timely assessments of student progress; it can also provide information on current workload and clinical commitments. Some possible lines of future development are discussed, including use of the system to collect Korner data‐sets and to support a more integrated approach to treatment.
Efficacy and Safety of Ciprofol for Sedation/Anesthesia in Patients Undergoing Hysteroscopy: A Randomized, Parallel-Group, Controlled Trial

Haiyan Lan,Weifeng Shan,Yini Wu,Qiaomin Xu,Xiaoli Dong,Peiyi Mei,Gongchen Duan,Minji You,Linfei Jin,Jimin Wu

DOI: https://doi.org/10.2147/DDDT.S414243

2023-06-11

Abstract:Haiyan Lan, Weifeng Shan, Yini Wu, Qiaomin Xu, Xiaoli Dong, Peiyi Mei, Gongchen Duan, Minji You, Linfei Jin, Jimin Wu Department of Anesthesiology, Lishui City People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, People's Republic of China Correspondence: Jimin Wu, Department of Anesthesiology, Lishui City People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, No. 15, Dazhong Street, Lishui, Zhejiang Province, 323000, People's Republic of China, Email Objective: To compare the efficacy and safety of ciprofol and propofol for sedation during hysteroscopy. Methods: A total of 149 patients undergoing hysteroscopy were randomly assigned to a ciprofol (Group C) or propofol group (Group P). All cases received intravenous sufentanil 0.1 μg/kg for analgesic preconditioning. Group C received an induction dose of ciprofol 0.4 mg/kg and a maintenance dosage of 0.6– 1.2 mg/kg/h to maintain BIS value between 40– 60. In Group P, propofol was started at 2.0 mg/kg and then maintained at 3.0– 6.0 mg/kg/h. The primary outcome was the successful rate of hysteroscopy. Secondary outcomes included the change of hemodynamic, respiratory adverse events, injection pain, body movement, recovery time, anesthetist's satisfaction, time of disappearance of the eyelash reflex and the incidence of nausea and vomiting. Results: The success rate of hysteroscopy in each group was 100%. After drug administration, the incidence of hypotension in Group C was much lower than that in Group P ( P < 0.05). The incidence of respiratory adverse events in Group C (4.0%) was much lower than that in Group P (31.1%) ( P < 0.05). The incidence of injection pain and body movement in Group C was significantly lower than that in Group P ( P < 0.05). The mean eyelash reflex disappearance time was less than 3 minutes in both groups. There was no statistically significant difference between the two groups in awakening times, anesthetist's satisfaction and the incidence of nausea and vomiting. No serious adverse events occurred in any patients. Conclusion: Ciprofol proved to be a safer alternative to propofol for anesthesia during hysteroscopy. In comparison to propofol, ciprofol does not cause injection pain, exerts less impact on hemodynamics, and results in less respiratory depression. Keywords: ciprofol, propofol, sedation, anesthesia, hysteroscopy Hysteroscopy is the most common procedure in minimally invasive gynecological techniques for the diagnosis and treatment of endometrial and other intrauterine diseases. 1 Despite the short duration of surgery, the intense pain associated with cervical dilation and endometrial curettage is excruciating, 2–4 and patients' fear and anxiety about pain require anesthetic intervention in most cases. 5,6 General anesthesia, paracervical block, and local anesthesia can be used for hysteroscopy. 7 Among these techniques, propofol combined with opioid intravenous anesthesia is used most commonly for hysteroscopic surgery. 8 This approach provides good sedation and analgesic effects for patients and also greatly reduces patients' anxiety and improves their comfort. Propofol has a rapid onset of action and short duration, and is associated with complete awakening and high patient comfort, making it suitable for outpatient surgery; 9,10 therefore, propofol has become the first choice for hysteroscopic procedures. However, propofol also has disadvantages, such as marked hemodynamic effects, respiratory depression, and painful intravenous administration. 11 Therefore, identification of the ideal sedative drug in hysteroscopic surgery remains crucial. Ciprofol (HSK 3486) is a novel 2,6 disubstituted phenol derivative that binds more tightly to the γ-aminobutyric acid type A receptor compared with propofol. 12 A Phase I study involving healthy Chinese participants showed that 0.4–0.9 mg/kg of ciprofol was well tolerated, with rapid onset of action and fast recovery. 13 The results of a Phase II clinical trial that investigated the efficacy and safety of ciprofol in colonoscopy showed that ciprofol was administered at a dose of only one-quarter to one-fifth that of propofol. Additionally, ciprofol had minimal residual effects and did not cause significant pain at the injection site. 14 Another trial of ciprofol in mechanically ventilated patients in the intensive care unit (ICU) determined the sedative effects and safety of ciprofol for this patient group. 15 The current trial was designed to confirm the efficacy and safety of ciprofol versus propofol during hysteroscopy, in the hope of providing a new safe and effective sedative drug for hysterosco -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal
Study of vancomycin tolerance in 120 strains of Streptococcus pneumoniae isolated in 1999 in Madrid, Spain.

N. Antón,R. Blázquez,J. Gómez-Garcés,J. Alós

DOI: https://doi.org/10.1093/JAC/47.6.902

2001-06-01

Journal of Antimicrobial Chemotherapy

Abstract:Sir, Streptococcus pneumoniae is a common cause of bacterial meningitis and of respiratory tract infections. Until the beginning of the 1980s the majority of pneumococcal strains were susceptible to penicillin, which was the treatment of choice. However, in recent years there have been reports of strains with structural changes to penicillin binding proteins (PBPs), reducing susceptibility not only to penicillin, but also to all other -lactam antibiotics. Some of these strains demonstrate MICs to penicillin of 0.1–1 mg/L (intermediate resistance), which allows the treatment of extrameningeal infections with higher than usual dosages of these antibiotics. However, the increase of strains with MICs 2 mg/L (considered resistant) raises the need for therapeutic alternatives. Spain, together with France and Hungary, is one of the European countries where most strains of pneumococci with diminished susceptibility to the penicillins have been isolated. In a study carried out between 1999 and 2000 in 10 of the 11 Health Authority Areas of Madrid with 300 strains of pneumococcus, 40.6% were found to be resistant and 25% intermediately resistant to penicillin. As long ago as 1994, 27% of the strains isolated from CSF and blood of children in Atlanta, GA, USA, had diminished sensitivity to penicillin and 13% were resistant to cefotaxime according to the NCCLS criteria. At present the American Academy of Pediatrics recommends the use of vancomycin in addition to a third-generation cephalosporin in those cases of meningitis where the agent is suspected to be S. pneumoniae. This recommendation has been extended to include the treatment of adults with meningitis. Recently, Novak et al. reported the existance of strains of S. pneumoniae tolerant to vancomycin, with clinical significance, albeit in an experimental rabbit model of meningitis. The data obtained from the study indicate that if tolerant strains invade the nervous system, they may be responsible for the relapse or persistence of bacterial meningitis. The objective of the present study was to evaluate the existence of this type of strain in clinical isolates in a country like Spain, where the prevalence of pneumococcus strains not susceptible to penicillin is high. Using a killing curve method, we evaluated vancomycin tolerance in 120 strains of S. pneumoniae isolated from clinical samples in 10 of the 11 Health Authority Areas of Madrid between 1999 and 2000. The MIC of vancomycin was determined in each strain by the agar dilution method, following NCCLS criteria. Each strain was inoculated in Mueller–Hinton broth and incubated at 37 C to reach an OD of 0.25–0.3 at 620 nm, corresponding with 5 10 cfu/mL. Once this concentration was obtained vancomycin was added to each culture to reach 10 MIC. After 3 h exposure time, 100 L were serially diluted in Davis medium and inoculated on to plates of Columbia sheep blood agar. The number of viable bacteria was determined at 0, 3 and 6 h in all strains, and at 0, 2, 4 and 8 h in 10 strains. Vancomycin tolerance was considered to exist if death of 2 0.6 log of the initial inoculum occurred at 6 h. Vancomycin tolerance was not detected in any of the 120 strains studied. The Figure presents, as an example, the killing curve of one of the strains studied. Although there is a high number of pneumococcus strains with diminished susceptibility to penicillin (intermediate or resistant) in Spain, strains tolerant to vancomycin have not yet been found. Nevertheless, it would be advisable to carry out this type of epidemiological study in order to detect the possible appearance of this type of strain with tolerance to vancomycin.
Antitumor effect of tumor necrosis factor against various primarily cultured human cancer cells.

N. Watanabe,Y. Niitsu,H. Neda,H. Sone,N. Yamauchi,T. Umetsu,I. Urushizaki

DOI: https://doi.org/10.20772/CANCERSCI1985.76.11_1115

1985-11-01

Abstract:The antitumor activity of tumor necrosis factor (TNF) against various primarily cultured human cancer cells (32 cases) was investigated by the 51Cr cytotoxic release assay and the tumor stem cell assay. Over 50% sensitivity (the ratio to the cytotoxicity in L929 cells) was noted in 4 of 14 cases of gastric cancer (28.6%), 7 of 9 cases of leukemic cells (77.8%), and 1 case each of pancreatic carcinoma and ovarian cancer. Scarcely any sensitivity, however, was observed in 1 case of acute promyelocytic leukemia or in some of the gastric cancer cases. No correlation was observed between the histological type of the cancer and TNF sensitivity. The above results seem to confirm that TNF has significant antitumor activity against human cancer cells.

Maternal Stress During Pregnancy and Offspring Depression.

Efficacy and safety of ciprofol (HSK3486) for procedural sedation and anesthesia induction in surgical patients: A systematic review and meta-analysis

Identification of testis specific calcineurin beta subunit isoform by a monoclonal antibody and detection of a specific six amino acid sequence.

The sensitivity index, a calculation to improve the choice of antibacterial therapy.

Efficacy and safety of Ciprofol compared with Propofol during general anesthesia induction: A systematic review and meta-analysis of randomized controlled trials (RCT)

Twenty-first century international lawmaking for alcohol control.

Efficacy and safety of ciprofol versus propofol for induction of general anaesthesia or sedation: A systematic review and meta-analysis of randomised controlled trials

Efficacy and Safety of Ciprofol Versus Propofol for the Induction of Anesthesia in Adult Patients: a Multicenter Phase 2a Clinical Trial

Effects of Ciprofol for the Induction of General Anesthesia in Patients Scheduled for Elective Surgery Compared to Propofol: a Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study

Efficacy and safety of ciprofol for sedation in outpatient gynecological procedures: a phase III multicenter randomized trial

Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial

Single-Artery Human Ear Graft Procurement: A Simplified Approach

Inhibitory Effect of Light on Growth-Supporting Properties of Eosin Methylene Blue Agar

Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial

The efficacy of ciprofol versus propofol on anesthesia in patients undergoing endoscopy: a systematic review and meta-analysis of randomized controlled trials

The characteristics of binding of human recombinant interferon-gamma to its receptor on human monocytes and human monocyte-like cell lines.

Ciprofol: A Novel Alternative to Propofol in Clinical Intravenous Anesthesia?

A role for computers in the management of dental education

Efficacy and Safety of Ciprofol for Sedation/Anesthesia in Patients Undergoing Hysteroscopy: A Randomized, Parallel-Group, Controlled Trial

Study of vancomycin tolerance in 120 strains of Streptococcus pneumoniae isolated in 1999 in Madrid, Spain.

Antitumor effect of tumor necrosis factor against various primarily cultured human cancer cells.